Cue Biopharma CUE 深 沪
已收盘 08-21 16:00:00 美东时间
23.98
-0.630
-2.56%
华盛通- 最 高26.00
- 今 开25.55
- 成交量 17.77万股
- 最 低 23.235
- 昨 收 24.61
- 总市值 1.74亿
- 52周最高 45.50
- 市盈率 静 --
- 换手率 2.45%
- 52周最低 4.971
- 委 比 -21.95%
- 总股本 726.44万
- 历史最高 950.70
- 量 比 0.84
- 振 幅 11.24%
- 历史最低 4.971
- 每 手 1
- 风险率 8.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share from the same period last year. The company reported quarterly sales of $7.877 milli...
08-15 04:27
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma reported second quarter 2026 financial results and business highlights, including the recent submission of an Investigational New Drug (IND) application for CUE-221 in food allergy applications, a $50 million private placement to support clinical development, and the appointment of new leadership. The company also announced Phase 2 data readouts for CUE-221 in Chronic Spontaneous Urticaria and plans to initiate a Phase 1 study for C...
08-14 20:05
Cue Biopharma Appoints James M. Ahlers CFO
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to President and Chief Executive Officer Shao-Lee Lin, ...
08-03 20:33
Cue Biopharma Announces $50 Million Private Placement
Cue Biopharma ( ($CUE) ) has issued an announcement. On July 9, 2026, Cue Bioph...
07-11 05:57
Cue Biopharma to raise $50M in oversubscribed private placement
Cue Biopharma (CUE) has entered into a definitive securities purchase agreement to raise approximately $50.0M in gross proceeds through a private placement with a group of accredited institutional inv...
07-10 16:08
Cue Biopharma Announces $50.0 Million Private Placement
Cue Biopharma, a clinical-stage biopharma company, has secured approximately $50 million through a private placement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments. The funds will support clinical development and general corporate purposes. The company aims to advance therapies targeting functional cures for immunological disorders. The private placement is expected to close on July 13, 2026,...
07-10 01:40
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma announced the transition of its board, with four independent directors resigning, and the appointment of Daniel Camardo and Viola Meehan. Camardo, a former CEO with a track record of successful drug launches, and Meehan, a seasoned CFO with expertise in strategic finance, will bring critical experience to support the company's growth and late-stage clinical capabilities. The company emphasized their contributions to advancing transf...
06-02 20:05
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies for immunological disorders, announced that its CEO, Shao-Lee Lin, will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. EDT in New York City. A live audio webcast and replay of the presentation will be available through Cue Biopharma’s Investor Relations website for 90 days. Cue Biopharma is a...
05-21 20:05
